Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 3041 - 3048 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC7609 | AGK 2 |
|
Selective inhibitor of SIRT2 (IC<sub>50</sub> = 3.5 <span class='symbol'>μ</span>M). Displays no activity at SIRT1 and SIRT3 at concentrations up to 40 <span class='symbol'>μ</span>M. Reduces <span class='symbol'>α</span>-synuclein-mediated toxicity in <em>in vitro</em> and <em>in vivo</em> models of Parkinson's disease.
|
|
| BCC7610 | CDPPB |
|
Brain penetrant, selective positive allosteric modulator at the mGlu<sub>5</sub> receptor (EC<sub>50</sub> values are 10 and 20 nM for human and rat receptors respectively). Antipsychotic; reverses amphetamine-induced locomotor activity and amphetamine-induced deficits in prepulse inhibition in rats.
|
|
| BCC7611 | PACAP 6-38 |
|
Potent and competitive pituitary adenylate cyclase-activating polypeptide receptor (PAC)<sub>1</sub> antagonist (IC<sub>50</sub> = 2 nM). Inhibits PACAP(1-27)-induced stimulation of adenylate cyclase (K<sub>i</sub> = 1.5 nM). Antitumor activity <em>in vivo</em>.
|
|
| BCC7612 | SCH 221510 |
|
Potent and selective nociceptin opioid receptor (NOP) agonist (EC<sub>50</sub> values are 12, 693, 683 and 8071 nM, and K<sub>i</sub> values are 0.3, 65, 131 and 2854 nM at NOP, <span class='symbol'>μ</span>-, <span class='symbol'>κ</span>- and <span class='symbol'>δ</span>-opioid receptors respectively). Exhibits anxiolytic-like activity at doses that have no effect on overt behaviors such as locomotion <em>in vivo</em>. Orally active.
|
|
| BCC7613 | BMS 193885 |
|
Potent, competitive neuropeptide (NPY) Y<sub>1</sub> antagonist (K<sub>i</sub> = 3.3 nM, IC<sub>50</sub> = 5.9 nM) that displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over <span class='symbol'>σ</span><sub>1</sub>, <span class='symbol'>α</span><sub>1</sub>, Y<sub>2</sub>, Y<sub>4</sub> and Y<sub>5</sub> receptors respectively. Reduces food intake and body weight via central Y<sub>1</sub> inhibition and is brain penetrant.
|
|
| BCC7614 | LY 354740 |
|
Highly selective and potent agonist of group II mGlu receptors (EC<sub>50</sub> values are 5.1 and 24.3 nM at mGlu<sub>2</sub> and mGlu<sub>3</sub> receptors respectively and > 100000 nM at mGlu<sub>4</sub>, mGlu<sub>7</sub>, mGlu<sub>1a</sub> and mGlu<sub>5a</sub> receptors). Displays antianxiety and antiaddictive activity <em>in vivo</em>. Orally and systemically active.
|
|
| BCC7615 | VU 0155041 |
|
Potent, positive allosteric modulator/allosteric agonist at mGlu<sub>4</sub> receptors (EC<sub>50</sub> = 798 and 693 nM at human and rat mGlu<sub>4</sub> receptors respectively). Active in <em>in vivo</em> models of Parkinson's disease following i.c.v. administration. Also available as sodium salt 3311.
|
|
| BCC7616 | Z-Cyclopentyl-AP4 |
|
Group III mGlu receptor agonist that exhibits higher potency at mGlu<sub>4</sub> than mGlu<sub>8</sub> (EC<sub>50</sub> values are 49 and 124 <span class='symbol'>μ</span>M respectively) with no activity at mGlu<sub>7</sub>. Selectively inhibits synaptic activity in the lateral perforant pathway (IC<sub>50</sub> values are 130 and 1859 <span class='symbol'>μ</span>M in the lateral and medial perforant pathways respectively). Conformationally restrained analog of L-AP4.
|
|